Artelo Biosciences (ARTL) announced its presentation of new data at the British Pain Conference held in Newport, Wales, UK on June 3-5, 2025 that further validates the therapeutic potential of Fatty Acid Binding Protein, FABP, inhibitors in treating osteoarthritis, OA, pain. Professor Saoirse O’Sullivan, Vice President of Translation Sciences at Artelo Biosciences, presented results from an animal study titled: “The Fatty Acid Binding Protein 5 Inhibitor ART26.12 is a Novel Analgesic for Osteoarthritis Pain.” The data builds upon an extensive set of pre-clinical data for ART26.12 that demonstrates analgesic and anti-nocicpetive effects in multiple models of pain.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARTL:
- Artelo Biosciences announces publication of paper on FABP inhibitor program
- Artelo Biosciences Reports Q1 2025 Financial Results
- Artelo Biosciences Faces Nasdaq Compliance Challenge
- Artelo Biosciences reports Q1 EPS (72c) vs (78c) last year
- Artelo Biosciences announces publication of peer-reviewed research on ART26.12